Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity

International Journal of Obesity

Volumn 36, Issue 6, 2012, Pages 880-885

  Gatta Cherifi, B ^a,b,c   Matias, I ^a,c   Vallee M ^a,c   Tabarin, A ^a,b,c   Marsicano, G ^a,c   Piazza, P V ^a,c   Cota, D ^a,c  

^a INSTITUT FRANÇOIS MAGENDIE   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

endocannabinoid; food intake; meal; PYY

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ENDOCANNABINOID; PEPTIDE YY;

ADULT; APPETITE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOOD INTAKE; HUMAN; INSULIN RESISTANCE; MALE; MEAL; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ADULT; APPETITE REGULATION; ARACHIDONIC ACIDS; BODY MASS INDEX; CANNABINOID RECEPTOR MODULATORS; EATING; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HUMANS; INSULIN RESISTANCE; MALE; OBESITY; PEPTIDE YY; POLYUNSATURATED ALKAMIDES; POSTPRANDIAL PERIOD;

EID: 84862167328     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2011.165     Document Type: Article

References (27)

1. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003; 299: 853-855. (Pubitemid 36182434)
2. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006; 443: 289-295. (Pubitemid 44435142)
3. Strader AD, Woods SC. Gastrointestinal hormones and food intake. Gastroenterology 2005; 128: 175-191. (Pubitemid 40039969)
4. Robinson JR, Niswender KD. What are the risks and the benefits of current and emerging weight-loss medications? Curr Diab Rep 2009; 9: 368-375.
5. Halford JC, Boyland EJ, Blundell JE, Kirkham TC, Harrold JA. Pharmacological management of appetite expression in obesity. Nat Rev Endocrinol 2010; 6: 255-269.
6. Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 2007; 23: 507-517. (Pubitemid 350018024)
7. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-589. (Pubitemid 40594198)
8. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843. (Pubitemid 41401077)
9. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007; 31: 692-699. (Pubitemid 46482358)
10. Jumpertz R, Guijarro A, Pratley RE, Piomelli D, Krakoff J. Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure. J Clin Endocrinol Metab 2011; 96: 115-121.
11. Karra E, Chandarana K, Batterham RL. The role of peptide YY in appetite regulation and obesity. J Physiol 2009; 587: 19-25.
12. le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, Wynne KJ et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006; 147: 3-8. (Pubitemid 43004254)
13. Lee HK, Choi EB, Pak CS. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr Top Med Chem 2009; 9: 482-503.
14. Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 2008; 1781: 200-212.
15. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171-3180. (Pubitemid 44271774)
16. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-1719. (Pubitemid 33641587)
17. Minowa S, Ishihara S, Tsuchiya S, Horie S, Murayama T. Capsaicin-and anandamide-induced gastric acid secretion via vanilloid receptor type 1 (TRPV1) in rat brain. Brain Res 2005; 1039: 75-83. (Pubitemid 40386829)
18. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-9617. (Pubitemid 35356203)
19. Delgado-Aros S, Cremonini F, Castillo JE, Chial HJ, Burton DD, Ferber I et al. Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology 2004; 126: 432-440 (Pubitemid 38182300)
20. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol 2009; 158: 451-461.
21. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948. (Pubitemid 37064767)
22. Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009; 161: 715-722.
23. White NE, Dhillo WS, Liu YL, Small CJ, Kennett GA, Gardiner JV et al. Co-administration of SR141716 with peptide YY3-36 or oxyntomodulin has additive effects on food intake in mice. Diabetes Obes Metab 2008; 10: 167-170.
24. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120: 2953-2966.
25. Son MH, Kim HD, Chae YN, Kim MK, Shin CY, Ahn GJ et al. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int J Obes (Lond) 2010; 34: 547-556.
26. Pavon FJ, Serrano A, Perez-Valero V, Jagerovic N, Hernandez-Folgado L, Bermudez-Silva FJ et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 2008; 20 (Suppl 1): 116-123. (Pubitemid 351552685)
27. Haas MJ. Peripheral CNR1 antagonists to the fore. Science-Business eXchange 2010; 3; http://www.nature.com/scibx/journal/v3/n32/full/scibx.2010. 972.html.